Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
| 0.42 | |
| 0.42 | |
| - | |
| 0.426 | |
| 0.401 | |
| 0.385-4.34 | |
| 2 981 K | |
| 7 000 K | |
| 4 693 K | |
| -1.69 | |
| 2.322 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says Petros Pharmaceuticals Inc (NASDAQ:PTPI) is a pharmaceutical co...
Delivers Overview of New Strategy for Leveraging AMMO’s Existing Assets and Evolving the Company into a Diversified, Growing and Profitable Ecommerce Powerhouse Highlights Long-Term Opportunity to ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
